← External Forces: Trade, Geopolitics & Market Access (all topics)
API & KSM import dependence
What it is
Active pharmaceutical ingredients and their key starting materials are the chemical base of formulations. India remains dependent on Chinese intermediates for many molecules despite being a large API producer
Bulk Drug PLI and China-plus-one sourcing both target that dependence
Impact on industries
- China-plus-one has moved genuine volume to Indian API producers, and Bulk Drug PLI has enabled domestic manufacture of KSMs previously imported entirely
- Complex chemistry, peptides and CRAMS work carry margins and customer stickiness that commodity APIs cannot
- Imported Chinese intermediates remain the base for many molecules, so the substitution is partial and the vulnerability persists upstream
- Environmental compliance carries closure risk, and molecule concentration means a patent expiry or lost approval removes a revenue line entirely
Industries affected
Pharmaceuticals-API & Bulk Drugs (Large & Medium)
CDMO & Contract Research
Speciality Chem-Fine Chemicals, Intermediates & CSM-Large (Large-Cap)
Speciality Chem-Fine Chemicals, Intermediates & CSM-Mid & Small
Pharmaceuticals-Formulations-Large (Large-Cap)
Pharmaceuticals-Formulations-Medium (Mid-Cap)